Hematology

Latest News

MDS | Image Credit: © ibreakstock-stock.adobe.com
Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

December 11th 2024

Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.

CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com
6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

December 10th 2024

New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com
Tattoos May Be Associated With Increased Risk of Rare NHLs

November 29th 2024

FDA Approval | image credit: gomixer - stock.adobe.com
FDA Approves Imatinib Oral Solution for Treatment of Various Cancers

November 26th 2024

Guidelines | Image Credit: © momius-stock.adobe.com
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma

November 26th 2024

More News

red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
September 4th 2024

B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

Kimberly Rath, PharmD
A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.
Telomeres act as protective caps on the ends of chromosomes | image credit: Anastasiia - stock.adobe.com
September 3rd 2024

RIOK2 Regulates Telomerase Subunits to Prevent Telomere Shortening

Gwen Mergian
New research linking telomere shortening to myelodysplastic syndromes (MDS) offers substantial therapeutic implications for affected patients and MDS research.
Despite treatment, some patients with PNH still experience anemia | image credit: ImageFlow - stock.adobe.com
August 28th 2024

Pegcetacoplan May Reduce Fatigue in PNH Accompanied by Anemia

Kyle Munz
Findings from a post hoc analysis of 3 clinical trials support the switching to or initiation of pegcetacoplan to manage fatigue for patients with paroxysmal nocturnal hemoglobinuria (PNH) that is accompanied by mild to moderate anemia.
Immunology word cloud | image credit: ibreakstock - stock.adobe.com
August 27th 2024

Researchers Identify Potential IO Targets in AML Through Surfaceome Analysis

AJMC Contributor
By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.
Cancerous cells | image credit: Dr_Microbe - stock.adobe.com
August 26th 2024

Multiplex Spatial Analysis Highlights Mechanisms of Refractory cHL

Jared Kaltwasser
Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.
Skin cancer is a dangerous morbidity risk in patients with CLL | image credit: Ocskay Mark - stock.adobe.com
August 26th 2024

Study Implicates AXL in Skin Cancer Development in CLL

Jared Kaltwasser
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
CLL cells | image credit: Arif Biswas - stock.adobe.com
August 19th 2024

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Nameera Temkar, MD
A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.
Quality of life in patients with hemophilia A or B benefits from the use of concizumab | image credit: Patrick Daxenbichler - stock.adobe.com
August 18th 2024

Patient-Reported Outcomes Favor Concizumab Prophylaxis in Hemophilia A or B

Connor Iapoce
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.
AML cells | image credit: LASZLO - stock.adobe.com
August 17th 2024

AML Treatment Has Shifted Toward More Personalized Approach

AJMC Contributor
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease.
Cytokine release concept | image credit: Bijac - stock.adobe.com
August 16th 2024

Cytokine Release Syndrome in CAR T-Cell Therapy: A Common Yet Controllable Complication in DLBCL

Kimberly Rath, PharmD
CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases.
Maria Amaya, MD, PhD
August 16th 2024

Real-World Outcomes Not Always Reflected in Clinical Trials: Dr Maria Amaya

Kyle Munz
Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.
Patients with PNH may become more active following ravulizumab therapy | image credit: sutadimages - stock.adobe.com
August 16th 2024

Ravulizumab Boosts Activity Levels, Quality of Life in Patients With PNH

Connor Iapoce
Ravulizumab therapy may enable patients with paroxysmal nocturnal hemoglobinuria (PNH) to comparable achieve activity levels and patient-reported outcomes to the US general population.
Guidelines folder | Image Credit: tashatuvango-stock.adobe.com
August 16th 2024

New Guidelines Clarify MDS Classification, Highlight Diagnostic Nuances

Gayle Turim Dickstein
Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.
FDA approval | Image Credit: Tada Images - stock.adobe.com
August 15th 2024

FDA Approves Axatilimab-csfr for Chronic Graft-vs-Host Disease

Cameron Santoro
The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments.
Anna Sureda, MD, PhD
August 10th 2024

Advancements in R/R Lymphoma: Bispecific Antibodies in Focus

Brooke McCormick Maggie L. Shaw
In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).
Precision medicine | Image Credit: leowolfert-stock.adobe.com
August 8th 2024

Opportunities Remain for Expanding Precision Medicine in CLL

AJMC Contributor
As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.
Sickle cell retinopathy is a manifestation of SCD that occurs in the eye and can cause detriments to patients’ vision| image credit: Катерина Євтехова - stock.adobe.com
August 5th 2024

The Benefits of More Sickle Cell Retinopathy Screening for Patients With SCD

Kyle Munz
A systematic analysis that reviewed screening for sickle cell retinopathy in patients with sickle cell disease (SCD) underscores the importance of advanced imaging measures and further research on screening implementation methods.
doc comforting patient | Image Credit: Seventyfour-stock.adobe.com
August 3rd 2024

Blinatumomab Boosts Survival in MRD-Negative BCP-ALL

Jared Kaltwasser
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.
MDS wooden blocks | Image Credit: Sviatlana - stock.adobe.com
August 2nd 2024

Report: ESAs Largely Ineffective in Lower-Risk MDS

Jared Kaltwasser
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).
doc interviewing patient | Image Credit: ChasingMagic/peopleimages.com-stock.adobe.com
August 1st 2024

Accurately Capturing Experiences of Patients With NHL

Jared Kaltwasser
Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).
FDA | Image Credit: ra2studio-stock.adobe.com
July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.
awareness of hematologic disorders | Image Credit: Orawan-stock.adobe.com
July 30th 2024

ActivinA Helps B-ALL Cells by Inducing Extracellular Vesicles

Jared Kaltwasser
A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).
stem cell transplant | Image Credit: Vadim-stock.adobe.com.jpeg
July 28th 2024

HCT Outcomes Show Improvement With Posttransplant Cyclophosphamide

Karen Jacobson-Sive
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.
Clinical link research | Image Credit: sdecoret - stock.adobe.com
July 27th 2024

MRD, Clinical Outcomes Linked in Chronic Leukemia

Gayle Turim Dickstein
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
pregnant woman who is too hot| Image Credit: Studio Romantic-stock.adobe.com
July 27th 2024

High Ambient Temperatures in Pregnancy Related to Childhood Leukemia Risk

Gayle Turim Dickstein
When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.
CAR T in MM | Image Credit: LASZLO-stock.adobe.com
July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw
This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).
Efanesoctocog alfa is a high-sustained factor VIII replacement therapy for the treatment of hemophilia A | image credit: Ekaterina - stock.adobe.com
July 25th 2024

Efanesoctocog Alfa Prophylaxis Promising for Pediatric Severe Hemophilia A

Kyle Munz
The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.
CAR T | Image Credit: Christoph Burgstedt-stock.adobe.com
July 23rd 2024

In LBCL, Barriers to CAR T Remain: SDOH and More

Gayle Turim Dickstein
The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.
<12345678
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo